When a patient or family member makes a discriminatory remark, many clinicians may not know how to respond. A presentation at the virtual 2021 Pediatric Academic Societies meeting looks at how algorithms could help.
The events of the past year have been a potent reminder of the prevalence of racism and discrimination that non-White Americans deal with on a daily basis. The recent statement from the Centers for Disease Control and Prevention that racism is a public health issue cements the need for the medical community to address these issues with patients, but what happens when the person experiencing the racism or discrimination is the health care provider or a colleague, and the one discriminating is a patient or a family member? At the virtual 2021 Pediatric Academic Societies meeting, Sahar Rahiem, MD, MHS, a resident at Texas Children’s Hospital and Baylor College of Medicine in Houston, discussed a model that she had created with colleagues to turn someone from a bystander to an upstander.
Rahiem and her colleagues began their research because discrimination from families or patients is common, accounting for 22% of discrimination faced by trainees, but poses a conundrum. Clinicians want to have a good rapport with patients because that improves care outcomes and likelihood of treatment compliance, but at the same time, they should be able to speak up if the patient or patient's caregiver are making biased comments. Futhermore, colleagues need to be supported, and a lack of response from a fellow clinician who was a witness to the exchange could be seen as not caring about the discrimination or even agreeing with the discrimination.
The model created by the team was taught in a workshop and included 3 steps:
Rahiem presented how the algorithm would work with a discriminatory statement. The first step is assessing the medical condition of the child. If the condition is unstable, clinicians should provide urgent medical treatment and have a debrief session later. If the child is stable, the clinician should determine how to respond based on whether the statement was overly discriminatory or was a microaggression. In the case of overt discrimination, a clinician should use “I” statements and make the position clear with a statement like “I’m asking you to not use that language while your child is being treated by our medical staff.” In cases of microaggressions, the clinician should reflect the statement back with an “I” statement such as “What I heard is that you think…” In both cases, the clinician should then move the conversation back to the child’s medical care. Following an encounter, a clinician should tell other colleagues about what occurred and a debriefing should happen.
According to Rahiem, the participants in the study found it very helpful with many indicating that the lessons learned in the workshop would lead to changes in clinical practice. Many of the participants also said that the algorithms used were helpful, with many commenting that they felt better equipped to handle situations in the future because of the
Reference
1. Rahiem ST. Moving from bystand to upstander: responding to discrimination from patients/families. Pediatric Academic Societies Meeting 2021; May 1, 2021; virtual. Accessed May 1, 2021.
Having "the talk" with teen patients
June 17th 2022A visit with a pediatric clinician is an ideal time to ensure that a teenager knows the correct information, has the opportunity to make certain contraceptive choices, and instill the knowledge that the pediatric office is a safe place to come for help.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Dupilumab safe, effective for up to 1 year for atopic dermatitis in infants, preschool children
May 3rd 2024According to new study data presented at the 2024 Pediatric Academic Societies Meeting, dupilumab (dupixent; Sanofi and Regeneron) demonstrated positive safety and efficacy results for up to 1 year in infants and preschool-age children with atopic dermatitis.